 Shares of Moderna Inc. rose 1.4 in premarket trading Tuesday, after the biotechnology company said it has partnered with Takeda Pharmaceutical Co. Ltd. and the Ministry of Health, Labour and Welfare of Japan to supply an additional 50 million doses of Modernas COVID-19 vaccine in 2022. 